The 3rd Microbiome Movement – Drug Development Europe (28-30 January 2019) returns as the industry-defining forum to help discover, develop and deliver the next generation of microbiome-based therapeutic and diagnostic candidates to market

Recent breakthroughs in DNA sequencing, metagenomic analysis and computational techniques have given scientists new insight into the structure and function of the human microbiota, an interconnected community of symbiotic, commensal and pathogenic microorganisms. As valuable clinical data solidifies the importance of the human microbiome on human health and disease, recent efforts have sought to harness this research to create microbiome-based therapeutics.

Situated at the heart of therapeutic R&D, the Microbiome Movement – Drug Development Summit kick starts 2019, once again to help large pharma, biotech and academic institutions accelerate the discovery, clinical development of safe, effective and commercially scalable microbiome therapeutics across a broad range of disease indications.

This meeting will show leading industry case studies focused on enhancing the application of novel technologies to standardise results, accelerate target discovery and optimise the translation of microbiome research into safe and effective therapeutic products.

One of the meeting fields is the development of the next-generation of microbiome therapeutics on the focus on microbial-derived bioactives, engineered bacterial strains and bacteriophage approaches. It is known that phages play a critical role in stabilizing bacterial balance in a human gut and may be used ac high-specific tools for microbiome correction.